Oklahoma Health Care Authority; Insulin Access and Affordability Program; effective date; emergency.
Summary
HB1380 creates the Insulin Access and Affordability Program within the Oklahoma Health Care Authority. The program is intended to increase competition in the insulin market, lower insulin prices, address shortages in generic prescription drugs, and improve access to affordable medications for Oklahoma residents, public purchasers, private purchasers, taxpayers, and consumers.
To carry out the program, the Authority may enter into agreements with nonprofit pharmaceutical companies registered with the U.S. Food and Drug Administration to speed development and affordability of fast-acting insulin. It may also contract with nonprofit organizations to set performance goals for low-cost biosimilar insulin, including target prices of no more than $30 per vial or $55 per five-pack of prefilled pens, and to document expected savings and any matching funds provided alongside state appropriations. The bill takes effect July 1, 2025, and contains an emergency clause for immediate effectiveness upon passage and approval.
Impact
The bill adds a new section to Title 63 of the Oklahoma Statutes establishing a state-run insulin affordability initiative under the Oklahoma Health Care Authority. It authorizes the agency to negotiate and contract with nonprofit entities to expand access to fast-acting and biosimilar insulin, potentially affecting drug procurement, pricing, and access for Oklahoma residents and self-insured purchasers. The measure does not directly regulate private insurers or pharmacies, but it creates a statutory framework for state-supported partnerships aimed at lowering prescription drug costs.
Sentiment
The available voting history suggests broad support for the bill. It passed the House Appropriations and Budget Committee unanimously, advanced on House third reading with a substantial majority, and later received a strong favorable vote in the Senate. The absence of committee transcript discussion limits insight into detailed debate, but the vote pattern indicates the measure was generally viewed positively as a health-care affordability initiative.
Contention
No specific points of contention are documented in the provided materials. Based on the bill text, any potential concerns would likely center on state spending, the use of appropriated funds, the reliance on nonprofit partners, and whether the program can deliver insulin at the stated price targets. However, the recorded votes show little visible opposition, suggesting any objections were limited or not prominent in the available record.